<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04788849</url>
  </required_header>
  <id_info>
    <org_study_id>UMilanoBicocca&amp;BD/Copan</org_study_id>
    <nct_id>NCT04788849</nct_id>
  </id_info>
  <brief_title>Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples</brief_title>
  <acronym>Ext-VALHUDES</acronym>
  <official_title>Extended VALidation of HUman Papillomavirus Assays and Collection DEvices for HPV Testing on Self-samples and First-void Urine Samples</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Becton, Dickinson and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>COPAN ITALIA SPA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sciensano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Europeo di Oncologia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Sassari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ATS Sardegna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Milano Bicocca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The &quot;Extended VALHUDES&quot; study is a Clinical Performance / Diagnostic Test Accuracy Study that&#xD;
      aims to extend validation, achieved as part of the &quot;Belgian VALHUDES&quot;, of HPV testing using&#xD;
      BD Onclarity on samples collected using Copan's devices for dry self-sampling of vaginal&#xD;
      material and for first-void urine: FLOQSwab® 5E089N and UriSponge™.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women accessing the Colposcopy Centres for a colposcopy examination and fulfilling the&#xD;
      selection criteria will be asked, after written informed consent, to self-collect a&#xD;
      first-void urine (with UriSponge™ 8E031S100 device) and a vaginal sample (with FLOQSwab®&#xD;
      5E089N device), prior to undergoing colposcopy. Just before colposcopic examination, a&#xD;
      clinician will also collect a cervical sample using a Cervex-Brush.&#xD;
&#xD;
      A colposcopy-targeted biopsy or histology following excisional treatment of a cervical&#xD;
      precancer lesion will be undertaken if appropriate. The colposcopy and/or histological&#xD;
      findings will be used as the gold standard. In case of normal satisfactory colposcopic&#xD;
      findings without biopsy taking, colposcopy will provide the study outcome.&#xD;
&#xD;
      Virological accuracy of HPV testing using: [a] BD Onclarity on FLOQSwab® 5E089N vaginal&#xD;
      self-samples, [b] BD Onclarity on UriSponge™ 8E031S100 urine specimens, will be compared to&#xD;
      BD Onclarity testing on a cervical samples collected by a clinician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analytical performance and Clinical accuracy</measure>
    <time_frame>One day, with possible extension if excision biopsy is planned based on the coloposcopy/histology outcome of tissue specimens collected at the enrolment visit.</time_frame>
    <description>Concordance of the presence of HPV and of the partial and extended HPV genotyping results applied on self- and clinician-collected samples.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Women's Acceptance and Preferences regarding urine collection, vaginal self-sampling or cervical sample collection by a clinician.</measure>
    <time_frame>One day</time_frame>
    <description>Acceptance and preferences regarding urine collection, vaginal self-sampling or clinicians' collected cervical samples will be assessed through a questionnaire administered to participating women at the time of colposcopy. The questionnaire will allow to determine the percentage of women expressing a preference for urine collection and/or vaginal self-sampling over clinicians' collected cervical samples.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cervical Intraepithelial Neoplasia Grade 2/3</condition>
  <condition>Carcinoma Cervix</condition>
  <arm_group>
    <arm_group_label>Women referred to colposcopy</arm_group_label>
    <description>Three sample types (urine, vaginal and cervical) will be collected from all enrolled women.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>BD Onclarity™ HPV assay</intervention_name>
    <description>Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample</description>
    <arm_group_label>Women referred to colposcopy</arm_group_label>
    <other_name>Copan's FLOQSwabs® 5E089N</other_name>
    <other_name>Copan's UriSponge™ 8E031S100</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Vaginal, urine and cervical samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Women with a recent history of abnormal Pap smear who are referred to colposcopy in one of&#xD;
        the 2 Italian Colposcopy Centres:&#xD;
&#xD;
          -  Istituto Europeo di Oncolgia (IEO), Milan&#xD;
&#xD;
          -  Coordinamento Consultori Familiari, ATS Sardegna&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women, referred to colposcopy due to abnormal Pap-test result, who agree to&#xD;
             participate in the study by signing an informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women younger than 25 or older than 64 years of age&#xD;
&#xD;
          -  Hysterectomized women&#xD;
&#xD;
          -  Women with known pregnancy&#xD;
&#xD;
          -  Non-consenting women&#xD;
&#xD;
          -  Women that are not able to understand and/or sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clementina E. Cocuzza, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine and Surgery, University of Milano-Bicocca</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marc Arbyn, MD</last_name>
    <phone>+3226425021</phone>
    <email>marc.arbyn@sciensano.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>IEO European Institute of Oncology</name>
      <address>
        <city>Milan</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna D Iacobone, MD</last_name>
      <phone>+39 02 57489.616</phone>
      <email>AnnaDaniela.Iacobone@ieo.it</email>
    </contact>
    <contact_backup>
      <last_name>Fabio Bottari, BSc</last_name>
      <phone>+39 02 94372716</phone>
      <email>fabio.bottari@ieo.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Coordinamento Consultori Familiari ASSL Sassari</name>
      <address>
        <city>Sassari</city>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto E Pietri, MD</last_name>
      <phone>+39 079 2062640</phone>
      <email>robertoenrico.pietri@atssardegna.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Arbyn M, Peeters E, Benoy I, Vanden Broeck D, Bogers J, De Sutter P, Donders G, Tjalma W, Weyers S, Cuschieri K, Poljak M, Bonde J, Cocuzza C, Zhao FH, Van Keer S, Vorsters A. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples. J Clin Virol. 2018 Oct;107:52-56. doi: 10.1016/j.jcv.2018.08.006. Epub 2018 Aug 22.</citation>
    <PMID>30195193</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014 Feb;15(2):172-83. doi: 10.1016/S1470-2045(13)70570-9. Epub 2014 Jan 14. Review.</citation>
    <PMID>24433684</PMID>
  </reference>
  <reference>
    <citation>Arbyn M, Smith SB, Temin S, Sultana F, Castle P; Collaboration on Self-Sampling and HPV Testing. Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses. BMJ. 2018 Dec 5;363:k4823. doi: 10.1136/bmj.k4823.</citation>
    <PMID>30518635</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 3, 2021</study_first_submitted>
  <study_first_submitted_qc>March 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Milano Bicocca</investigator_affiliation>
    <investigator_full_name>Clementina Cocuzza</investigator_full_name>
    <investigator_title>Associate Professor of Clinical Microbiology</investigator_title>
  </responsible_party>
  <keyword>Self-Sampling</keyword>
  <keyword>HPV testing</keyword>
  <keyword>Diagnostic Test Accuarcy</keyword>
  <keyword>Cervical Cancer Screening</keyword>
  <keyword>Cervical Intraepithelial Neoplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study protocol and results will be published at a later date</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

